CS MEDICA A/S: CS MEDICA announces that their 6 CANNANSEN®CBD Medical Products has been successfully registered at MHRA for Sales in United Kingdom.


The registration of the 6 CANNANSEN® CBD medicinal products with the MHRA enables CS MEDICA to market and sell their 6 CANNANSEN® CBD medicinal products in the UK. The registration has further significance for the company's efforts to achieve brand awareness globally.

"The registration at the MHRA in the UK  is an important step for CS MEDICA as the UK works as a display market for Australia, MENA (Middle East and North Africa) and other countries where the local health authorities use the UK as a reference country. Hence the MHRA registration is an significant mark in our efforts to create global awareness and sale," Lone Henriksen, CEO CS MEDICA comments.